Epilepsy treatment drug fycompa is on the market in Belgium

Source: pharmacogeographic 2014-08-06 the first brand-new partial seizure (the most common type of epilepsy) treatment drug fycompa (perampanel) was launched in Belgium on August 4 The drug can be used for the adjuvant treatment of partial seizures (with or without secondary systemic seizures) of 12 years old or above Perampanel is the only approved antiepileptic drug (AED) that selectively acts on AMPA receptor, which plays a key role in brain during epileptic attack This mechanism is different from other existing antiepileptic drugs In addition, perampanel is administered once a day before going to bed, which is convenient to take More importantly, it is the only new generation of drugs approved for marketing to treat partial seizures in adolescents over 12 years old Epilepsy is one of the most common neurological diseases in the world In Belgium, about 60000 people have epilepsy, and 150000 have had seizures at some point Although there are many drugs for epilepsy, the incidence rate of partial epilepsy is still high, and the cure is still a huge challenge At present, 20% - 40% of patients diagnosed with epilepsy are difficult to cure "We are pleased to announce the listing of perampanel in Belgium As a new leader in the field of epilepsy treatment, Weicai company is committed to developing innovative therapies to meet the needs of patients with epilepsy These patients need alternative therapies to help them control their seizures, "said Dr Nicolas kormoss, medical director of Weicai in Belgium and Luxembourg Perampanel was approved in Belgium based on three randomized, double-blind, placebo-controlled, dose-increasing global phase III clinical trials (304 / 305 / 306) and an open label extension study (307) Research shows that perampanel, as an adjuvant treatment for partial epilepsy (with or without secondary systemic seizures), has consistent results in efficacy and long-term tolerance The most common adverse reactions were dizziness, drowsiness, fatigue, headache, falls, irritability and ataxia The results of public label expansion study also showed that perampanel was effective and well tolerated.